Doxorubicin Market is expected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% from 2022.
/PRNewswire/ Padagis today announced the FDA approval and launch of an AB-rated generic version of Doxil® (Doxorubicin Liposome Injection) through its.
/PRNewswire/ Padagis today announced the FDA approval and launch of an AB-rated generic version of Doxil® (Doxorubicin Liposome Injection) through its.